106 442

Cited 6 times in

Effect of neoadjuvant chemotherapy on overall survival of patients with T2-4aN0M0 bladder cancer: A systematic review and meta-analysis according to EAU COVID-19 recommendation

DC Field Value Language
dc.contributor.author이주용-
dc.contributor.author조강수-
dc.contributor.author문영준-
dc.date.accessioned2022-05-09T17:18:57Z-
dc.date.available2022-05-09T17:18:57Z-
dc.date.issued2022-04-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/188505-
dc.description.abstractPurpose: In the context of the COVID-19 outbreak, the European Association of Urology (EAU) guidelines Rapid Reaction Group provided recommendations to manage muscle invasive bladder cancer (MIBC) based on priority levels: neoadjuvant chemotherapy (NAC) should be avoided for patients with T2-3N0M0 MIBC. This meta-analysis aims to evaluate the efficacy of NAC compared with radical cystectomy (RC) alone in improving the overall survival (OS) of patients with T2-4aN0M0 MIBC. Materials and methods: A systematic review was performed according to the PRISMA guidelines. The PubMed/Medline, EMBASE, and Cochrane Library databases were searched. The primary outcome was OS of patients with T2-4aN0M0 MIBC, and the secondary outcome was OS of patients with only T2N0M0 MIBC. Results: Eight studies were included in this meta-analysis. Overall, the quality of all studies was relatively high, and little publication bias was demonstrated. The OS was significantly better in the NAC with RC group than in RC alone (HR, 0.79; 95% CI, 0.68-0.92; p = 0.002). A subgroup analysis was performed on only patients with T2N0M0 MIBC, and five studies were included. There was no difference in the OS between the NAC with RC and the RC alone groups (HR, 0.83; 95% CI, 0.69-1.01 p = 0.06). Conclusions: As recommended by the EAU guidelines Rapid Reaction Group, patients with T2N0M0 MIBC should strongly consider omitting NAC until the end of the COVID-19 pandemic. Whether to omit NAC in T3-4aN0M0 MIBC needs further discussion, and studies targeting only T2-3N0M0 MIBC are expected to proceed further.-
dc.description.statementOfResponsibilityopen-
dc.formatapplication/pdf-
dc.languageEnglish-
dc.publisherPublic Library of Science-
dc.relation.isPartOfPLOS ONE-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHCOVID-19*-
dc.subject.MESHCystectomy-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHMale-
dc.subject.MESHNeoadjuvant Therapy-
dc.subject.MESHNeoplasm Invasiveness-
dc.subject.MESHPandemics-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHUrinary Bladder Neoplasms* / drug therapy-
dc.subject.MESHUrinary Bladder Neoplasms* / surgery-
dc.subject.MESHUrology*-
dc.titleEffect of neoadjuvant chemotherapy on overall survival of patients with T2-4aN0M0 bladder cancer: A systematic review and meta-analysis according to EAU COVID-19 recommendation-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Urology (비뇨의학교실)-
dc.contributor.googleauthorDong Hyuk Kang-
dc.contributor.googleauthorKang Su Cho-
dc.contributor.googleauthorYoung Joon Moon-
dc.contributor.googleauthorDoo Yong Chung-
dc.contributor.googleauthorHae Do Jung-
dc.contributor.googleauthorJoo Yong Lee-
dc.identifier.doi10.1371/journal.pone.0267410-
dc.contributor.localIdA03161-
dc.contributor.localIdA03801-
dc.relation.journalcodeJ02540-
dc.identifier.eissn1932-6203-
dc.identifier.pmid35446917-
dc.contributor.alternativeNameLee, Joo Yong-
dc.contributor.affiliatedAuthor이주용-
dc.contributor.affiliatedAuthor조강수-
dc.citation.volume17-
dc.citation.number4-
dc.citation.startPagee0267410-
dc.identifier.bibliographicCitationPLOS ONE, Vol.17(4) : e0267410, 2022-04-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Urology (비뇨의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.